Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA (NYSE: IQV) announced it was ranked No. 1 in Everest Group’s “Top 50™ Pharmaceutical Technology Providers” report for 2026, earning an overall score of 96.8 out of 100. The recognition highlights IQVIA’s technology coverage across all six assessed pharmaceutical value-chain areas, from drug discovery and clinical development to manufacturing, commercialization, supply chain and pharmacovigilance.
IQVIA (NYSE:IQV) and clinical-stage biopharma company Medera announced a strategic collaboration to accelerate development of cardiac gene therapies and human-based drug discovery platforms. IQVIA will provide global clinical trial, regulatory and commercialization support to Medera’s Sardocor gene therapy programs and Novoheart mini-Heart platform.
According to the companies, Sardocor will use IQVIA’s expertise to advance FDA-cleared, first-in-human AAV-based gene therapy trials and pursue expedited FDA designations. Novoheart’s engineered human cardiac tissue platform, already used to secure IND and Fast Track designations, is expanding to multiple organ systems under the FDA Modernization Act 2.0.
IQVIA (NYSE:IQV) reported second-quarter 2026 revenue of $4,368 million, up 8.7% year-over-year (8.5% constant currency). Commercial Solutions revenue was $1,793 million (+8.6%), while Research & Development Solutions (R&DS) revenue reached $2,575 million (+8.8%).
R&DS net new bookings were $3.15 billion, up 19% year-over-year, producing a 1.22x book-to-bill and contributing to a contracted backlog of $34.2 billion, with about $9.2 billion expected to convert to revenue in the next 12 months. GAAP net income attributable to IQVIA was $256 million (diluted EPS $1.53), and Adjusted EBITDA was $994 million, up 9.2%. Adjusted diluted EPS was $3.15, up 12.1%.
Operating cash flow rose 26.0% to $558 million, and free cash flow increased 23.3% to $360 million. IQVIA repurchased $398 million of shares in the quarter and $950 million in the first half. The company raised its full-year 2026 guidance, now targeting revenue of $17.28–$17.48 billion, Adjusted EBITDA of $4.00–$4.05 billion, and Adjusted diluted EPS of $12.80–$13.00.
IQVIA (NYSE:IQV) reported that Dr. Cynthia Verst, president of Design and Delivery Innovation, Research and Development Solutions, testified before the U.S. House Committee on Energy and Commerce Subcommittee on Health during a hearing on FDA’s role in advancing U.S. drug development.
Dr. Verst recommended measures to make the U.S. a stronger destination for early clinical development, including a clearer path from discovery to first-in-human studies, risk‑proportionate approaches, and more timely scientific advice. She emphasized modernizing early clinical development, enabling more flexible, iterative FDA interactions, and expanding support for emerging biopharmaceutical companies that account for more than 75% of new Phase I trial starts.
Additional proposals included defining fit‑for‑purpose minimum datasets for safe‑to‑proceed decisions, improving bench‑to‑clinic infrastructure across public and private stakeholders, and enhancing patient finding and trial matching while preserving privacy. IQVIA plans continued collaboration with Congress, FDA, HHS, sponsors, investigators and patient groups to help bring potential medicines to patients faster.
IQVIA (NYSE:IQV) will release its Q2 2026 financial results before the market opens on Tuesday, July 28, 2026. Management will host a conference call and webcast at 9:00 a.m. ET, with materials and replay available on the IQVIA investor relations website.
IQVIA (NYSE:IQV) and Wiley released a cross-sector report, “Scientific Discovery & AI: The Science-to-Patient Journey.” The report distills insights from a May 2026 summit with 25+ senior leaders across pharma, academia, health systems, technology and publishing.
It highlights AI’s role across four stages of the healthcare value chain and five high-potential directions, while also noting incentive misalignments that can slow patient impact.
IQVIA (NYSE:IQV) priced an offering of €950 million senior notes due 2033 through its subsidiary IQVIA Inc. The notes carry a 4.625% coupon, pay interest semi-annually from December 15, 2026, and are expected to close around June 11, 2026.
Proceeds will refinance existing debt and cover related fees.
IQVIA (NYSE:IQV) plans an offering of €950,000,000 senior notes due 2033 through subsidiary IQVIA Inc. Proceeds are expected to refinance existing indebtedness and cover related fees and expenses.
The notes will be sold in a private placement under Rule 144A and Regulation S, subject to market and customary conditions.
IQVIA (NYSE:IQV) announced that chairman and CEO Ari Bousbib will speak at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:20 a.m. ET.
A live audio webcast and same-day replay will be accessible via the IQVIA investor relations website.
IQVIA (NYSE:IQV) and Kexing Biopharm (688136.SH) are expanding a strategic collaboration to support a global, multi-product biosimilar development and commercialization program. The alliance combines IQVIA’s end-to-end clinical, regulatory, analytics and commercialization capabilities with its AI-enabled clinical trial platform to streamline protocol design, site selection and study conduct for Kexing’s international expansion.